Novel supramolecular CRISPR-Cas9 carrier enables more efficient genome editing

In a recent paper published in June 2022 in Volume 27 of Applied Materials Today, a research team from Kumamoto University has developed a transformable polyrotaxane (PRX) carrier that can facilitate genome editing using Cas9RNP with high efficiency and usability. "While there have been some PRX-based drug carriers for nucleic acids and proteins reported before, this is the first report on PRX-based Cas9 RNP carrier. Moreover, our findings describe how to precisely control intracellular dynamics across multiple steps. This will prove invaluable for future research in this direction," says Professor Keiichi Motoyama, a corresponding author of the paper.

For their novel carrier, the research team focused on PRX with amine groups, i.e. amino-PRX, and went through multiple rounds of development and optimization before achieving their final product. For example, the first generation (1G) of their carrier molecules, exploited the autonomous transforming properties of amino-PRX to efficiently complex it with Cas9 RNP and enable its delivery past the cell membrane. The second generation (2G) worked towards endosome-escape. This was achieved via the transformation of the amino-groups in amino-PRX into highly cationic (positively charged) particles within the endosome, which resulted in the rupturing of the endosome and the escape of Cas9 RNP-amino-PRX. The next few generations addressed problems relating to the release of Cas9 once the complex had escaped the endosome. Finally, they developed the fifth generation (5G) multi-step transformable amino-PRX carrier that could precisely and efficiently deliver Cas9 RNP into the cell nucleus. The research team further performed in vitro and in vivo experiments to confirm the cytotoxicity of the system, as well as its genome editing efficiency. "Our delivery system has a low cytotoxicity and its genome editing activity is equal to the current most efficient system on the market," reveals Associate Professor Taishi Higashi of Kumamoto University, who is the other corresponding author of the study. "Moreover, our multiple attempts at optimizing the delivery system across generations offers important information on the types and positions of various biodegradable groups and amino groups that can be used in such a system to further customize and adapt their properties."

The autonomous action, multi-step transformable properties, and low cytotoxicity of the 5G amino-PRX carrier make it an enormously promising candidate for the safe and efficient delivery of Cas9 RNP. These findings could furthermore be applied for the delivery of a wide range of molecules, such as enzymes, antibodies, and small interfering RNA (siRNA), thereby making this novel carrier a significant achievement in the field of drug and vaccine development.